Sequence of events in prostate #cancer, by @MarkARubin1
http://www.Nature.com/articles/d41586-018-06029-5 Discusses the high prevalence of AR-enhancer amplifications in recent studies
QT:{{”
“Quigley and colleagues performed whole-genome sequencing of 101 samples of metastatic, castration-resistant prostate-cancer tissue obtained from previous studies11,12. The most frequently altered genomic site identified was the AR-enhancer region, which was amplified in 81% of samples. The high prevalence of this type of amplification is notable because enhancer amplifications identified so far for other cancer types generally arise at much lower
frequency13–16. Moreover, the high prevalence of this AR-enhancer amplification in the data presented by Viswanathan and Quigley contrasts with its occurrence in only 1 of 54 previously published whole-genome sequences of prostate-cancer samples obtained before clinical treatment had commenced17.”
“}}
Posts Tagged ‘encodec’
Sequence of events in prostate cancer
October 5, 2018New study finds cell line difference across labs
August 16, 2018https://www.nature.com/articles/s41586-018-0409-3
QT:{{”
“… comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic
diversification. Similar results were obtained with multiple strains of 13 additional cell lines.
“}}
genome-wide starr-seq + sources of experimental bias
August 12, 2018quite relevant
https://www.nature.com/articles/nmeth.4534
Resolving systematic errors in widely used enhancer activity assays in human cells
Felix Muerdter
, Łukasz M Boryń
, Ashley R Woodfin
, Christoph Neumayr
, Martina Rath
, Muhammad A Zabidi
, Michaela Pagani
, Vanja Haberle
, Tomáš Kazmar
, Rui R Catarino
, Katharina Schernhuber
, Cosmas D Arnold
& Alexander Stark
Nature Methods volume 15, pages141–149 (2018)
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
June 15, 2018Commentary
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data Carolyn Hutter + Jean Claude Zenklusen
https://www.sciencedirect.com/science/article/pii/S009286741830374X
Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies – ScienceDirect
April 28, 2018Genome-Scale Signatures of Gene Interaction from #CompoundScreens Predict…Efficacy of Targeted Cancer Therapies
https://www.ScienceDirect.com/science/article/pii/S2405471218300097 How to find drug combos: Find expression response profiles associated w/ a drug target. A synergistic drug might change profiles similarly
ncdriver and ENCODE
March 17, 2018Received: 13 November 2017 Revised: 22 November 2017 Accepted: 29 November 2017 https://www.nature.com/articles/s41525-017-0040-5.pdf
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma | Nature Genetics
February 11, 2018Chromatin states define tumour-specific T cell dysfunction and reprogramming | Nature
November 19, 2017STAR Methods
September 28, 2017Here is the STAR Methods format (Structured, Transparent, Accessible Reporting) introduced last year by Cell, marketed as a structure that “promotes transparent reporting of experimental design and
methodological details.” Details are in the links below.
Editorial: http://www.cell.com/cell/fulltext/S0092-8674(16)31072-8 Instructions: http://www.cell.com/star-authors-guide
Website: http://www.cell.com/star-methods
US cancer institute to overhaul tumour cell lines
July 9, 2017QT:{{"
“The NCI will continue to supply the NCI-60 cell lines to researchers, but will eventually refocus its drug screening on newer models. It is developing hundreds of ‘patient-derived xenografts’ (PDXs), which are created by implanting small chunks of human tumours into mice. There, the tumours grow in an environment that, although not human, better mimics their native environment”
"}}
